Takeda Pharmaceutical Ltd ADR TAK

$17.86 0.00 (—)

Valuation

Market cap
57,228,496,000
Revenue TTM
$29,737,750,000
Net income TTM
$-1,005,770,000
PE ratio
10.63
Forward PE
11.45
Profit margin
-3.38%
Debt to equity
0.65

Trading

Volume
2,132,700
Avg volume
2,789,386
Day's range
$17.78 – $17.89
Shares out
3,204,283,000
Stochastic %K
6%
Beta
-0.07
Analysts
Strong Sell
Price target
$21.97

Price

Company profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Re...

Show more

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
81 3 3278 2111
Website
https://www.takeda.com
Address
1-1, Nihonbashi-Honcho 2-chome, Chuo, Japan

Latest news

Stocktwits

SparkyReturns Oct 2, 2:38 PM
$MRNA Biotech investors, have a breaking investment idea. ICU I can't believe the broader market is sleeping on this. Saves half of the people who would otherwise die from sepsis due to cytokine storm. Billions in TAM, about to roll out not just for kids but soon for adults in 2027 and no one realizes the import. 6 Breakthrough Device Designations ranging from Kidney, to Cardio, to Respiratory. Unreal we got in on the ground floor. $TAK $ABBV $BAYRY $PFE
0 replies
ajbski Sep 30, 4:37 PM
$NVAX will achieve full profitably by 2028 with Nuvaxovid partnership ($SNY $TAK ) deals. When other catalysts/deals are announced (Oncology; C. Diff., CIC, Pfizer, etc…), it’s going to rocket to $100+++. 🚀🚀🚀 https://share.google/aimode/qLY3jWklPhJDNRpsz
0 replies
Merlintrader Sep 29, 11:31 PM
Plasma: $ADMA, $GRFS, $CSLLY, $TAK and immune protection https://www.merlintrader.com/plasma-adma-grfs-cslly-tak-immunoglobulins/
0 replies
Sambong Sep 27, 6:00 AM
$TAK coming up from a year base. above 20. worth a look
0 replies
Merlintrader Sep 25, 6:45 PM
Narcolepsy after the orexin approval: $ALKS, $AXSM, $JAZZ and $TAK https://www.merlintrader.com/narcolepsy-orexin-alks-axsm-jazz-tak/
0 replies
NVDAMillionaire Sep 24, 6:23 AM
$TAK Really good write-up that perfectly summarizes TAK's present situation. So if you want to bring your TAK knowledge up to date or just discover TAK, this is required reading. https://everyticker.com/quote/TAK/analysis/tak-s-horizon-one-finale-why-fy2026-s-margin-sacrifice-sets-up-transformative-growth
0 replies
JuggernautRaider Sep 22, 6:44 PM
Me neither 🤫 🧐 $ALT $CGTX $TAK $TNXP 🍱
0 replies
Quantumup Sep 21, 12:32 PM
Stifel reiterated $ALKS Buy-$63 and said -- We are reiterating our Buy rating on ALKS following positive signals in the ph1b from ALKS 7290, their orexin agonist for ADHD. CNTA - $LLY $TAK SUPN OTSKY AXSM Stifel added—In the 2wk study in ADHD patients, '7290 demonstrated AISRS reductions from baseline of 14/19points for the 20/50mg dose cohorts, and a 1-2point reduction in CGI-S, which, for 2 week efficacy, looks strong in the context of other studies (better than Strattera, nearing stimulants). The important caveat here though is that we do not know how this compares to placebo (which was not disclosed in the PR); we followed up with ALKS who emphasized that there were only 8 placebo completers here in what was a small (N = 50) study where patients were 4:1 randomized to active or placebo. We assume the placebo effect was significant, but big picture we still think orexins have real potential in ADHD, given the data and also validating precedent from other narcolepsy drugs.
0 replies